#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Cortical	_
1-2	9-19	substrates	_
1-3	20-22	of	_
1-4	23-37	cue-reactivity	_
1-5	38-40	in	_
1-6	41-49	multiple	_
1-7	50-59	substance	_
1-8	60-69	dependent	_
1-9	70-81	populations	_
1-10	82-83	:	_
1-11	84-99	transdiagnostic	_
1-12	100-109	relevance	_
1-13	110-112	of	_
1-14	113-116	the	_
1-15	117-123	medial	_
1-16	124-134	prefrontal	_
1-17	135-141	cortex	_
1-18	142-150	Elevated	_
1-19	151-159	drug-cue	_
1-20	160-168	elicited	_
1-21	169-174	brain	_
1-22	175-183	activity	_
1-23	184-186	is	_
1-24	187-190	one	_
1-25	191-193	of	_
1-26	194-197	the	_
1-27	198-202	most	_
1-28	203-209	widely	_
1-29	210-215	cited	_
1-30	216-217	,	_
1-31	218-237	transdiagnostically	_
1-32	238-246	relevant	_
1-33	247-253	traits	_
1-34	254-256	of	_
1-35	257-266	substance	_
1-36	267-276	dependent	_
1-37	277-288	populations	_
1-38	289-290	.	_

2-1	291-296	These	_
2-2	297-308	populations	_
2-3	309-310	,	_
2-4	311-318	however	_
2-5	319-320	,	_
2-6	321-324	are	_
2-7	325-334	typically	_
2-8	335-342	studied	_
2-9	343-345	in	_
2-10	346-355	isolation	_
2-11	356-357	.	_

3-1	358-361	The	_
3-2	362-366	goal	_
3-3	367-369	of	_
3-4	370-374	this	_
3-5	375-380	study	_
3-6	381-384	was	_
3-7	385-387	to	_
3-8	388-401	prospectively	_
3-9	402-413	investigate	_
3-10	414-417	the	_
3-11	418-425	spatial	_
3-12	426-436	topography	_
3-13	437-439	of	_
3-14	440-448	drug-cue	_
3-15	449-459	reactivity	_
3-16	460-462	in	_
3-17	463-464	a	_
3-18	465-470	large	_
3-19	471-474	set	_
3-20	475-477	of	_
3-21	478-489	individuals	_
3-22	490-499	dependent	_
3-23	500-502	on	_
3-24	503-509	either	_
3-25	510-517	cocaine	_
3-26	518-519	,	_
3-27	520-527	alcohol	_
3-28	528-529	,	_
3-29	530-532	or	_
3-30	533-541	nicotine	_
3-31	542-543	.	_

4-1	544-554	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-2	555-558	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-3	559-563	data	_
4-4	564-567	was	_
4-5	568-576	acquired	_
4-6	577-581	from	_
4-7	582-585	156	_
4-8	586-595	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-9	596-605	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-10	606-617	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-11	618-619	(	_
4-12	620-622	55	_
4-13	623-630	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-14	631-632	,	_
4-15	633-635	53	_
4-16	636-643	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-17	644-645	,	_
4-18	646-649	and	_
4-19	650-652	48	_
4-20	653-661	nicotine	_
4-21	662-663	)	_
4-22	664-666	as	_
4-23	667-671	they	_
4-24	672-681	performed	_
4-25	682-683	a	_
4-26	684-696	standardized	_
4-27	697-705	drug-cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-28	706-714	exposure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-29	715-719	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-30	720-721	.	_

5-1	722-730	Clusters	_
5-2	731-733	of	_
5-3	734-745	significant	_
5-4	746-756	activation	_
5-5	757-759	to	_
5-6	760-769	drug-cues	_
5-7	770-778	relative	_
5-8	779-781	to	_
5-9	782-789	neutral	_
5-10	790-794	cues	_
5-11	795-796	(	_
5-12	797-798	‘	_
5-13	799-802	hot	_
5-14	803-808	spots	_
5-15	809-810	’	_
5-16	811-812	)	_
5-17	813-817	were	_
5-18	818-826	isolated	_
5-19	827-830	for	_
5-20	831-835	each	_
5-21	836-846	individual	_
5-22	847-848	.	_

6-1	849-856	K-means	_
6-2	857-867	clustering	_
6-3	868-871	was	_
6-4	872-876	used	_
6-5	877-879	to	_
6-6	880-888	classify	_
6-7	889-892	the	_
6-8	893-900	spatial	_
6-9	901-911	topography	_
6-10	912-914	of	_
6-11	915-918	the	_
6-12	919-927	hotspots	_
6-13	928-930	in	_
6-14	931-934	the	_
6-15	935-939	data	_
6-16	940-943	set	_
6-17	944-945	.	_

7-1	946-949	The	_
7-2	950-960	percentage	_
7-3	961-963	of	_
7-4	964-972	hotspots	_
7-5	973-977	that	_
7-6	978-983	would	_
7-7	984-986	be	_
7-8	987-994	reached	_
7-9	995-997	at	_
7-10	998-1005	several	_
7-11	1006-1015	distances	_
7-12	1016-1017	(	_
7-13	1018-1021	2–5	_
7-14	1022-1024	cm	_
7-15	1025-1026	)	_
7-16	1027-1029	of	_
7-17	1030-1042	transcranial	_
7-18	1043-1051	magnetic	_
7-19	1052-1063	stimulation	_
7-20	1064-1065	(	_
7-21	1066-1069	TMS	_
7-22	1070-1071	)	_
7-23	1072-1076	were	_
7-24	1077-1087	calculated	_
7-25	1088-1089	.	_

8-1	1090-1093	One	_
8-2	1094-1101	hundred	_
8-3	1102-1105	and	_
8-4	1106-1111	three	_
8-5	1112-1124	participants	_
8-6	1125-1128	had	_
8-7	1129-1131	at	_
8-8	1132-1137	least	_
8-9	1138-1141	one	_
8-10	1142-1149	cluster	_
8-11	1150-1152	of	_
8-12	1153-1164	significant	_
8-13	1165-1172	frontal	_
8-14	1173-1179	cortex	_
8-15	1180-1188	activity	_
8-16	1189-1190	(	_
8-17	1191-1193	66	_
8-18	1194-1195	%	_
8-19	1196-1197	)	_
8-20	1198-1199	.	_

9-1	1200-1207	K-means	_
9-2	1208-1216	revealed	_
9-3	1217-1218	3	_
9-4	1219-1227	distinct	_
9-5	1228-1236	clusters	_
9-6	1237-1243	within	_
9-7	1244-1247	the	_
9-8	1248-1254	medial	_
9-9	1255-1265	prefrontal	_
9-10	1266-1272	cortex	_
9-11	1273-1274	(	_
9-12	1275-1279	MPFC	_
9-13	1280-1281	)	_
9-14	1282-1283	,	_
9-15	1284-1288	left	_
9-16	1289-1297	inferior	_
9-17	1298-1305	frontal	_
9-18	1306-1318	gyrus/insula	_
9-19	1319-1320	,	_
9-20	1321-1326	right	_
9-21	1327-1335	premotor	_
9-22	1336-1342	cortex	_
9-23	1343-1344	.	_

10-1	1345-1348	For	_
10-2	1349-1352	the	_
10-3	1353-1358	group	_
10-4	1359-1361	as	_
10-5	1362-1363	a	_
10-6	1364-1369	whole	_
10-7	1370-1371	(	_
10-8	1372-1375	and	_
10-9	1376-1379	for	_
10-10	1380-1387	alcohol	_
10-11	1388-1393	users	_
10-12	1394-1397	and	_
10-13	1398-1406	nicotine	_
10-14	1407-1412	users	_
10-15	1413-1426	independently	_
10-16	1427-1428	)	_
10-17	1429-1430	,	_
10-18	1431-1437	medial	_
10-19	1438-1448	prefrontal	_
10-20	1449-1455	cortex	_
10-21	1456-1457	(	_
10-22	1458-1460	BA	_
10-23	1461-1463	10	_
10-24	1464-1465	)	_
10-25	1466-1469	was	_
10-26	1470-1473	the	_
10-27	1474-1482	location	_
10-28	1483-1485	of	_
10-29	1486-1489	the	_
10-30	1490-1498	greatest	_
10-31	1499-1505	number	_
10-32	1506-1508	of	_
10-33	1509-1517	hotspots	_
10-34	1518-1519	.	_

11-1	1520-1523	The	_
11-2	1524-1531	frontal	_
11-3	1532-1536	pole	_
11-4	1537-1540	was	_
11-5	1541-1549	cortical	_
11-6	1550-1558	location	_
11-7	1559-1566	closest	_
11-8	1567-1569	to	_
11-9	1570-1573	the	_
11-10	1574-1581	largest	_
11-11	1582-1592	percentage	_
11-12	1593-1595	of	_
11-13	1596-1604	hotspots	_
11-14	1605-1606	.	_

12-1	1607-1612	While	_
12-2	1613-1618	there	_
12-3	1619-1621	is	_
12-4	1622-1632	individual	_
12-5	1633-1644	variability	_
12-6	1645-1647	in	_
12-7	1648-1651	the	_
12-8	1652-1660	location	_
12-9	1661-1663	of	_
12-10	1664-1667	the	_
12-11	1668-1680	cue-elicited	_
12-12	1681-1682	‘	_
12-13	1683-1686	hot	_
12-14	1687-1691	spot	_
12-15	1692-1693	’	_
12-16	1694-1699	these	_
12-17	1700-1704	data	_
12-18	1705-1716	demonstrate	_
12-19	1717-1721	that	_
12-20	1722-1730	elevated	_
12-21	1731-1735	BOLD	_
12-22	1736-1742	signal	_
12-23	1743-1745	to	_
12-24	1746-1750	drug	_
12-25	1751-1755	cues	_
12-26	1756-1758	in	_
12-27	1759-1762	the	_
12-28	1763-1767	MPFC	_
12-29	1768-1771	may	_
12-30	1772-1774	be	_
12-31	1775-1776	a	_
12-32	1777-1792	transdiagnostic	_
12-33	1793-1806	endophenotype	_
12-34	1807-1809	of	_
12-35	1810-1819	addiction	_
12-36	1820-1825	which	_
12-37	1826-1829	may	_
12-38	1830-1834	also	_
12-39	1835-1837	be	_
12-40	1838-1839	a	_
12-41	1840-1848	fruitful	_
12-42	1849-1864	neuromodulation	_
12-43	1865-1871	target	_
12-44	1872-1873	.	_

13-1	1874-1880	Method	_
13-2	1881-1893	Participants	_
13-3	1894-1897	For	_
13-4	1898-1902	this	_
13-5	1903-1916	investigation	_
13-6	1917-1921	data	_
13-7	1922-1925	was	_
13-8	1926-1936	aggregated	_
13-9	1937-1941	from	_
13-10	1942-1946	four	_
13-11	1947-1955	separate	_
13-12	1956-1970	investigations	_
13-13	1971-1973	of	_
13-14	1974-1978	drug	_
13-15	1979-1993	cue-reactivity	_
13-16	1994-2003	performed	_
13-17	2004-2006	at	_
13-18	2007-2010	the	_
13-19	2011-2018	Medical	_
13-20	2019-2029	University	_
13-21	2030-2032	of	_
13-22	2033-2038	South	_
13-23	2039-2047	Carolina	_
13-24	2048-2049	(	_
13-25	2050-2054	MUSC	_
13-26	2055-2056	)	_
13-27	2057-2061	from	_
13-28	2062-2071	2012–2017	_
13-29	2072-2073	.	_

14-1	2074-2076	In	_
14-2	2077-2081	each	_
14-3	2082-2084	of	_
14-4	2085-2090	these	_
14-5	2091-2098	studies	_
14-6	2099-2112	non-treatment	_
14-7	2113-2117	drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-8	2118-2123	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-9	2124-2125	(	_
14-10	2126-2133	chronic	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
14-11	2134-2141	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
14-12	2142-2147	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
14-13	2148-2149	(	_
14-14	2150-2151	n	_
14-15	2152-2153	=	_
14-16	2154-2156	55	_
14-17	2157-2158	)	_
14-18	2159-2160	,	_
14-19	2161-2166	heavy	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
14-20	2167-2174	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
14-21	2175-2180	users	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
14-22	2181-2182	(	_
14-23	2183-2184	n	_
14-24	2185-2186	=	_
14-25	2187-2189	53	_
14-26	2190-2191	)	_
14-27	2192-2193	,	_
14-28	2194-2197	and	_
14-29	2198-2205	current	_
14-30	2206-2215	cigarette	_
14-31	2216-2223	smokers	_
14-32	2224-2225	(	_
14-33	2226-2227	n	_
14-34	2228-2229	=	_
14-35	2230-2232	48	_
14-36	2233-2234	)	_
14-37	2235-2236	)	_
14-38	2237-2241	were	_
14-39	2242-2251	recruited	_
14-40	2252-2256	from	_
14-41	2257-2260	the	_
14-42	2261-2271	Charleston	_
14-43	2272-2273	,	_
14-44	2274-2276	SC	_
14-45	2277-2289	metropolitan	_
14-46	2290-2294	area	_
14-47	2295-2300	using	_
14-48	2301-2314	word-of-mouth	_
14-49	2315-2326	advertising	_
14-50	2327-2330	and	_
14-51	2331-2338	digital	_
14-52	2339-2342	and	_
14-53	2343-2348	print	_
14-54	2349-2354	media	_
14-55	2355-2356	.	_

15-1	2357-2360	The	_
15-2	2361-2372	recruitment	_
15-3	2373-2374	,	_
15-4	2375-2382	consent	_
15-5	2383-2384	,	_
15-6	2385-2388	and	_
15-7	2389-2396	initial	_
15-8	2397-2407	functional	_
15-9	2408-2411	MRI	_
15-10	2412-2420	scanning	_
15-11	2421-2428	session	_
15-12	2429-2432	for	_
15-13	2433-2436	all	_
15-14	2437-2439	of	_
15-15	2440-2445	these	_
15-16	2446-2453	studies	_
15-17	2454-2457	was	_
15-18	2458-2468	consistent	_
15-19	2469-2470	.	_

16-1	2471-2473	To	_
16-2	2474-2476	be	_
16-3	2477-2485	eligible	_
16-4	2486-2498	participants	_
16-5	2499-2505	needed	_
16-6	2506-2508	to	_
16-7	2509-2511	be	_
16-8	2512-2517	21–60	_
16-9	2518-2523	years	_
16-10	2524-2527	old	_
16-11	2528-2531	and	_
16-12	2532-2536	meet	_
16-13	2537-2545	criteria	_
16-14	2546-2549	for	_
16-15	2550-2558	nicotine	_
16-16	2559-2560	,	_
16-17	2561-2568	alcohol	_
16-18	2569-2570	,	_
16-19	2571-2573	or	_
16-20	2574-2581	cocaine	_
16-21	2582-2592	dependence	_
16-22	2593-2594	.	_

17-1	2595-2607	Exclusionary	_
17-2	2608-2616	criteria	_
17-3	2617-2621	were	_
17-4	2622-2629	related	_
17-5	2630-2632	to	_
17-6	2633-2640	medical	_
17-7	2641-2648	history	_
17-8	2649-2652	and	_
17-9	2653-2656	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
17-10	2657-2663	safety	_
17-11	2664-2673	including	_
17-12	2674-2679	known	_
17-13	2680-2687	history	_
17-14	2688-2690	of	_
17-15	2691-2701	neurologic	_
17-16	2702-2709	disease	_
17-17	2710-2711	,	_
17-18	2712-2721	currently	_
17-19	2722-2729	meeting	_
17-20	2730-2736	DSM-IV	_
17-21	2737-2745	criteria	_
17-22	2746-2749	for	_
17-23	2750-2761	psychiatric	_
17-24	2762-2769	disease	_
17-25	2770-2771	(	_
17-26	2772-2777	other	_
17-27	2778-2782	than	_
17-28	2783-2792	substance	_
17-29	2793-2803	dependence	_
17-30	2804-2805	)	_
17-31	2806-2807	,	_
17-32	2808-2811	and	_
17-33	2812-2817	metal	_
17-34	2818-2826	implants	_
17-35	2827-2832	above	_
17-36	2833-2836	the	_
17-37	2837-2842	waist	_
17-38	2843-2845	or	_
17-39	2846-2853	history	_
17-40	2854-2856	of	_
17-41	2857-2858	a	_
17-42	2859-2866	gunshot	_
17-43	2867-2869	or	_
17-44	2870-2878	shrapnel	_
17-45	2879-2881	in	_
17-46	2882-2885	the	_
17-47	2886-2890	skin	_
17-48	2891-2892	.	_

18-1	2893-2905	Specifically	_
18-2	2906-2907	,	_
18-3	2908-2913	after	_
18-4	2914-2917	the	_
18-5	2918-2925	initial	_
18-6	2926-2931	phone	_
18-7	2932-2939	contact	_
18-8	2940-2943	all	_
18-9	2944-2955	individuals	_
18-10	2956-2960	were	_
18-11	2961-2968	invited	_
18-12	2969-2971	to	_
18-13	2972-2973	a	_
18-14	2974-2983	screening	_
18-15	2984-2989	visit	_
18-16	2990-2997	wherein	_
18-17	2998-3002	they	_
18-18	3003-3011	provided	_
18-19	3012-3018	signed	_
18-20	3019-3027	informed	_
18-21	3028-3035	consent	_
18-22	3036-3044	approved	_
18-23	3045-3047	by	_
18-24	3048-3051	the	_
18-25	3052-3056	MUSC	_
18-26	3057-3070	Institutional	_
18-27	3071-3077	Review	_
18-28	3078-3083	Board	_
18-29	3084-3087	and	_
18-30	3088-3097	completed	_
18-31	3098-3099	a	_
18-32	3100-3106	series	_
18-33	3107-3109	of	_
18-34	3110-3119	screening	_
18-35	3120-3131	assessments	_
18-36	3132-3137	which	_
18-37	3138-3147	evaluated	_
18-38	3148-3153	their	_
18-39	3154-3161	medical	_
18-40	3162-3168	health	_
18-41	3169-3170	,	_
18-42	3171-3182	psychiatric	_
18-43	3183-3189	health	_
18-44	3190-3191	,	_
18-45	3192-3195	and	_
18-46	3196-3200	drug	_
18-47	3201-3204	use	_
18-48	3205-3212	history	_
18-49	3213-3214	.	_

19-1	3215-3220	Basic	_
19-2	3221-3232	demographic	_
19-3	3233-3236	and	_
19-4	3237-3241	drug	_
19-5	3242-3245	use	_
19-6	3246-3253	history	_
19-7	3254-3256	of	_
19-8	3257-3262	these	_
19-9	3263-3268	three	_
19-10	3269-3275	groups	_
19-11	3276-3279	are	_
19-12	3280-3289	presented	_
19-13	3290-3292	in	_
19-14	3293-3298	Table	_
19-15	3299-3300	1	_
19-16	3301-3302	.	_

20-1	3303-3312	Following	_
20-2	3313-3316	the	_
20-3	3317-3326	screening	_
20-4	3327-3332	visit	_
20-5	3333-3334	,	_
20-6	3335-3338	all	_
20-7	3339-3351	participants	_
20-8	3352-3356	were	_
20-9	3357-3364	invited	_
20-10	3365-3367	to	_
20-11	3368-3369	a	_
20-12	3370-3376	second	_
20-13	3377-3382	visit	_
20-14	3383-3390	wherein	_
20-15	3391-3395	they	_
20-16	3396-3401	would	_
20-17	3402-3409	receive	_
20-18	3410-3412	an	_
20-19	3413-3416	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-20	3417-3421	scan	_
20-21	3422-3431	assessing	_
20-22	3432-3437	their	_
20-23	3438-3444	neural	_
20-24	3445-3453	response	_
20-25	3454-3456	to	_
20-26	3457-3461	drug	_
20-27	3462-3466	cues	_
20-28	3467-3475	tailored	_
20-29	3476-3478	to	_
20-30	3479-3484	their	_
20-31	3485-3491	stated	_
20-32	3492-3496	drug	_
20-33	3497-3499	of	_
20-34	3500-3506	choice	_
20-35	3507-3508	(	_
20-36	3509-3516	cocaine	_
20-37	3517-3518	,	_
20-38	3519-3526	alcohol	_
20-39	3527-3528	,	_
20-40	3529-3531	or	_
20-41	3532-3541	cigarette	_
20-42	3542-3543	)	_
20-43	3544-3545	.	_

21-1	3546-3549	All	_
21-2	3550-3562	participants	_
21-3	3563-3567	were	_
21-4	3568-3573	asked	_
21-5	3574-3576	to	_
21-6	3577-3584	refrain	_
21-7	3585-3589	from	_
21-8	3590-3595	using	_
21-9	3596-3603	cocaine	_
21-10	3604-3606	or	_
21-11	3607-3614	alcohol	_
21-12	3615-3617	on	_
21-13	3618-3621	the	_
21-14	3622-3625	day	_
21-15	3626-3628	of	_
21-16	3629-3632	the	_
21-17	3633-3636	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-18	3637-3645	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-19	3646-3653	session	_
21-20	3654-3657	and	_
21-21	3658-3665	smoking	_
21-22	3666-3676	cigarettes	_
21-23	3677-3678	2	_
21-24	3679-3680	h	_
21-25	3681-3687	before	_
21-26	3688-3691	the	_
21-27	3692-3700	scanning	_
21-28	3701-3708	session	_
21-29	3709-3710	.	_

22-1	3711-3716	Urine	_
22-2	3717-3721	drug	_
22-3	3722-3729	screens	_
22-4	3730-3734	were	_
22-5	3735-3739	used	_
22-6	3740-3742	to	_
22-7	3743-3749	verify	_
22-8	3750-3760	abstinence	_
22-9	3761-3765	from	_
22-10	3766-3773	cocaine	_
22-11	3774-3775	.	_

23-1	3776-3783	Exhaled	_
23-2	3784-3790	carbon	_
23-3	3791-3799	monoxide	_
23-4	3800-3806	levels	_
23-5	3807-3811	were	_
23-6	3812-3820	measured	_
23-7	3821-3825	with	_
23-8	3826-3827	a	_
23-9	3828-3844	Micro-Smokelyzer	_
23-10	3845-3846	(	_
23-11	3847-3854	Bedfont	_
23-12	3855-3865	Scientific	_
23-13	3866-3870	Ltd.	_
23-14	3871-3872	,	_
23-15	3873-3877	Kent	_
23-16	3878-3879	,	_
23-17	3880-3882	UK	_
23-18	3883-3884	)	_
23-19	3885-3888	and	_
23-20	3889-3896	exhaled	_
23-21	3897-3904	alcohol	_
23-22	3905-3908	was	_
23-23	3909-3917	measured	_
23-24	3918-3923	using	_
23-25	3924-3936	Breathalyzer	_
23-26	3937-3938	(	_
23-27	3939-3947	BACTrack	_
23-28	3948-3949	)	_
23-29	3950-3951	.	_

24-1	3952-3964	Drug/alcohol	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-2	3965-3968	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-3	3969-3979	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-4	3980-3984	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-5	3985-3989	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-6	3990-3993	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-7	3994-4002	drug-cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-8	4003-4013	reactivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-9	4014-4018	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-10	4019-4022	was	_
24-11	4023-4028	based	_
24-12	4029-4031	on	_
24-13	4032-4037	prior	_
24-14	4038-4042	work	_
24-15	4043-4044	[	_
24-16	4045-4046	,	_
24-17	4047-4048	]	_
24-18	4049-4050	.	_

25-1	4051-4053	In	_
25-2	4054-4057	the	_
25-3	4058-4061	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-4	4062-4073	environment	_
25-5	4074-4086	participants	_
25-6	4087-4093	viewed	_
25-7	4094-4100	blocks	_
25-8	4101-4103	of	_
25-9	4104-4111	cocaine	_
25-10	4112-4113	,	_
25-11	4114-4121	alcohol	_
25-12	4122-4123	,	_
25-13	4124-4126	or	_
25-14	4127-4134	smoking	_
25-15	4135-4139	cues	_
25-16	4140-4143	and	_
25-17	4144-4151	neutral	_
25-18	4152-4160	pictures	_
25-19	4161-4162	(	_
25-20	4163-4166	e.g	_
25-21	4167-4168	.	_

26-1	4169-4176	pencils	_
26-2	4177-4178	,	_
26-3	4179-4185	dishes	_
26-4	4186-4187	)	_
26-5	4188-4193	color	_
26-6	4194-4201	matched	_
26-7	4202-4205	for	_
26-8	4206-4209	hue	_
26-9	4210-4211	,	_
26-10	4212-4222	brightness	_
26-11	4223-4224	,	_
26-12	4225-4228	and	_
26-13	4229-4237	contrast	_
26-14	4238-4239	.	_

27-1	4240-4245	These	_
27-2	4246-4250	task	_
27-3	4251-4257	blocks	_
27-4	4258-4262	were	_
27-5	4263-4274	interleaved	_
27-6	4275-4279	with	_
27-7	4280-4287	control	_
27-8	4288-4294	blocks	_
27-9	4295-4296	(	_
27-10	4297-4305	fixation	_
27-11	4306-4311	cross	_
27-12	4312-4313	,	_
27-13	4314-4321	blurred	_
27-14	4322-4328	images	_
27-15	4329-4330	)	_
27-16	4331-4332	.	_

28-1	4333-4336	The	_
28-2	4337-4341	task	_
28-3	4342-4345	was	_
28-4	4346-4358	administered	_
28-5	4359-4361	in	_
28-6	4362-4365	the	_
28-7	4366-4369	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-8	4370-4377	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
28-9	4378-4380	as	_
28-10	4381-4382	a	_
28-11	4383-4388	block	_
28-12	4389-4395	design	_
28-13	4396-4401	using	_
28-14	4402-4409	E-Prime	_
28-15	4410-4418	software	_
28-16	4419-4420	(	_
28-17	4421-4431	Psychology	_
28-18	4432-4440	Software	_
28-19	4441-4446	Tools	_
28-20	4447-4448	,	_
28-21	4449-4453	Inc.	_
28-22	4454-4455	)	_
28-23	4456-4457	.	_

29-1	4458-4461	The	_
29-2	4462-4467	total	_
29-3	4468-4472	task	_
29-4	4473-4477	time	_
29-5	4478-4481	was	_
29-6	4482-4484	12	_
29-7	4485-4489	mins	_
29-8	4490-4493	and	_
29-9	4494-4503	consisted	_
29-10	4504-4506	of	_
29-11	4507-4510	six	_
29-12	4511-4521	120-second	_
29-13	4522-4528	epochs	_
29-14	4529-4530	.	_

30-1	4531-4535	Each	_
30-2	4536-4541	epoch	_
30-3	4542-4550	included	_
30-4	4551-4562	alternating	_
30-5	4563-4572	24-second	_
30-6	4573-4579	blocks	_
30-7	4580-4582	of	_
30-8	4583-4587	four	_
30-9	4588-4592	task	_
30-10	4593-4603	conditions	_
30-11	4604-4605	:	_
30-12	4606-4610	Drug	_
30-13	4611-4612	,	_
30-14	4613-4620	Neutral	_
30-15	4621-4622	,	_
30-16	4623-4627	Blur	_
30-17	4628-4629	,	_
30-18	4630-4633	and	_
30-19	4634-4638	Rest	_
30-20	4639-4640	.	_

31-1	4641-4653	Respectively	_
31-2	4654-4655	,	_
31-3	4656-4661	these	_
31-4	4662-4666	task	_
31-5	4667-4677	conditions	_
31-6	4678-4686	included	_
31-7	4687-4693	images	_
31-8	4694-4696	of	_
31-9	4697-4705	cocaine-	_
31-10	4706-4708	or	_
31-11	4709-4724	alcohol-related	_
31-12	4725-4732	stimuli	_
31-13	4733-4743	customized	_
31-14	4744-4747	for	_
31-15	4748-4752	each	_
31-16	4753-4758	group	_
31-17	4759-4760	(	_
31-18	4761-4764	e.g	_
31-19	4765-4766	.	_

32-1	4767-4772	crack	_
32-2	4773-4777	pipe	_
32-3	4778-4781	for	_
32-4	4782-4789	cocaine	_
32-5	4790-4795	users	_
32-6	4796-4797	;	_
32-7	4798-4804	liquor	_
32-8	4805-4812	bottles	_
32-9	4813-4816	for	_
32-10	4817-4824	alcohol	_
32-11	4825-4830	users	_
32-12	4831-4832	)	_
32-13	4833-4834	;	_
32-14	4835-4842	neutral	_
32-15	4843-4850	stimuli	_
32-16	4851-4852	(	_
32-17	4853-4856	e.g	_
32-18	4857-4858	.	_

33-1	4859-4864	glass	_
33-2	4865-4867	of	_
33-3	4868-4873	water	_
33-4	4874-4875	,	_
33-5	4876-4883	cooking	_
33-6	4884-4892	utensils	_
33-7	4893-4894	,	_
33-8	4895-4901	people	_
33-9	4902-4908	eating	_
33-10	4909-4915	dinner	_
33-11	4916-4917	)	_
33-12	4918-4919	;	_
33-13	4920-4927	blurred	_
33-14	4928-4935	stimuli	_
33-15	4936-4942	acting	_
33-16	4943-4945	as	_
33-17	4946-4952	visual	_
33-18	4953-4961	controls	_
33-19	4962-4964	by	_
33-20	4965-4973	matching	_
33-21	4974-4983	substance	_
33-22	4984-4990	images	_
33-23	4991-4993	in	_
33-24	4994-4999	color	_
33-25	5000-5003	and	_
33-26	5004-5007	hue	_
33-27	5008-5009	;	_
33-28	5010-5013	and	_
33-29	5014-5015	a	_
33-30	5016-5024	fixation	_
33-31	5025-5030	cross	_
33-32	5031-5034	for	_
33-33	5035-5040	alert	_
33-34	5041-5045	rest	_
33-35	5046-5053	periods	_
33-36	5054-5055	.	_

34-1	5056-5062	During	_
34-2	5063-5067	each	_
34-3	5068-5072	task	_
34-4	5073-5078	block	_
34-5	5079-5080	,	_
34-6	5081-5082	5	_
34-7	5083-5089	images	_
34-8	5090-5094	were	_
34-9	5095-5104	presented	_
34-10	5105-5106	(	_
34-11	5107-5110	4.8	_
34-12	5111-5112	s	_
34-13	5113-5114	)	_
34-14	5115-5116	.	_

35-1	5117-5122	Image	_
35-2	5123-5134	acquisition	_
35-3	5135-5150	High-resolution	_
35-4	5151-5162	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-5	5163-5173	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-6	5174-5180	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-7	5181-5185	were	_
35-8	5186-5194	acquired	_
35-9	5195-5198	for	_
35-10	5199-5203	each	_
35-11	5204-5215	participant	_
35-12	5216-5217	(	_
35-13	5218-5221	3.0	_
35-14	5222-5223	T	_
35-15	5224-5231	Siemens	_
35-16	5232-5236	Trio	_
35-17	5237-5238	,	_
35-18	5239-5241	3D	_
35-19	5242-5246	SPGR	_
35-20	5247-5248	,	_
35-21	5249-5251	TR	_
35-22	5252-5253	=	_
35-23	5254-5256	10	_
35-24	5257-5259	ms	_
35-25	5260-5261	,	_
35-26	5262-5264	TE	_
35-27	5265-5266	=	_
35-28	5267-5268	3	_
35-29	5269-5271	ms	_
35-30	5272-5273	,	_
35-31	5274-5279	voxel	_
35-32	5280-5290	dimensions	_
35-33	5291-5294	1.0	_
35-34	5295-5296	×	_
35-35	5297-5300	1.0	_
35-36	5301-5302	×	_
35-37	5303-5306	1.5	_
35-38	5307-5309	mm	_
35-39	5310-5311	,	_
35-40	5312-5315	256	_
35-41	5316-5317	×	_
35-42	5318-5321	256	_
35-43	5322-5328	voxels	_
35-44	5329-5330	,	_
35-45	5331-5334	124	_
35-46	5335-5341	slices	_
35-47	5342-5343	)	_
35-48	5344-5345	.	_

36-1	5346-5349	The	_
36-2	5350-5354	head	_
36-3	5355-5358	was	_
36-4	5359-5369	positioned	_
36-5	5370-5375	along	_
36-6	5376-5379	the	_
36-7	5380-5392	canthomeatal	_
36-8	5393-5397	line	_
36-9	5398-5399	.	_

37-1	5400-5404	Foam	_
37-2	5405-5412	padding	_
37-3	5413-5416	was	_
37-4	5417-5421	used	_
37-5	5422-5424	to	_
37-6	5425-5430	limit	_
37-7	5431-5435	head	_
37-8	5436-5442	motion	_
37-9	5443-5444	.	_

38-1	5445-5447	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
38-2	5448-5449	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
38-3	5450-5458	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
38-4	5459-5466	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
38-5	5467-5471	data	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
38-6	5472-5476	were	_
38-7	5477-5485	acquired	_
38-8	5486-5492	during	_
38-9	5493-5496	the	_
38-10	5497-5499	12	_
38-11	5500-5503	min	_
38-12	5504-5518	cue-reactivity	_
38-13	5519-5523	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
38-14	5524-5525	(	_
38-15	5526-5528	TR	_
38-16	5529-5530	=	_
38-17	5531-5534	2.2	_
38-18	5535-5536	,	_
38-19	5537-5539	TE	_
38-20	5540-5541	=	_
38-21	5542-5544	35	_
38-22	5545-5547	ms	_
38-23	5548-5549	,	_
38-24	5550-5552	64	_
38-25	5553-5554	×	_
38-26	5555-5557	64	_
38-27	5558-5559	,	_
38-28	5560-5561	3	_
38-29	5562-5564	mm	_
38-30	5565-5574	isotropic	_
38-31	5575-5581	voxels	_
38-32	5582-5583	)	_
38-33	5584-5585	.	_

39-1	5586-5598	Neuroimaging	_
39-2	5599-5603	data	_
39-3	5604-5612	analysis	_
39-4	5613-5616	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-5	5617-5621	data	_
39-6	5622-5626	were	_
39-7	5627-5639	preprocessed	_
39-8	5640-5645	using	_
39-9	5646-5651	SPM12	_
39-10	5652-5653	(	_
39-11	5654-5662	Wellcome	_
39-12	5663-5673	Department	_
39-13	5674-5676	of	_
39-14	5677-5686	Cognitive	_
39-15	5687-5696	Neurology	_
39-16	5697-5698	,	_
39-17	5699-5705	London	_
39-18	5706-5707	,	_
39-19	5708-5710	UK	_
39-20	5711-5712	)	_
39-21	5713-5724	implemented	_
39-22	5725-5727	in	_
39-23	5728-5734	Matlab	_
39-24	5735-5739	7.14	_
39-25	5740-5741	(	_
39-26	5742-5751	MathWorks	_
39-27	5752-5753	,	_
39-28	5754-5758	Inc.	_
39-29	5759-5760	,	_
39-30	5761-5767	Natick	_
39-31	5768-5769	,	_
39-32	5770-5772	MA	_
39-33	5773-5774	)	_
39-34	5775-5776	.	_

40-1	5777-5779	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-2	5780-5786	Images	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-3	5787-5791	were	_
40-4	5792-5797	first	_
40-5	5798-5807	converted	_
40-6	5808-5812	from	_
40-7	5813-5818	DICOM	_
40-8	5819-5825	format	_
40-9	5826-5828	to	_
40-10	5829-5831	4D	_
40-11	5832-5837	NIfTI	_
40-12	5838-5843	files	_
40-13	5844-5847	and	_
40-14	5848-5854	motion	_
40-15	5855-5864	corrected	_
40-16	5865-5866	(	_
40-17	5867-5874	Realign	_
40-18	5875-5876	:	_
40-19	5877-5878	6	_
40-20	5879-5888	parameter	_
40-21	5889-5899	rigid-body	_
40-22	5900-5911	realignment	_
40-23	5912-5914	to	_
40-24	5915-5920	first	_
40-25	5921-5926	image	_
40-26	5927-5929	in	_
40-27	5930-5934	each	_
40-28	5935-5945	timeseries	_
40-29	5946-5951	using	_
40-30	5952-5953	a	_
40-31	5954-5967	least-squares	_
40-32	5968-5976	approach	_
40-33	5977-5978	)	_
40-34	5979-5980	.	_

41-1	5981-5994	Normalization	_
41-2	5995-6005	parameters	_
41-3	6006-6007	,	_
41-4	6008-6012	bias	_
41-5	6013-6023	correction	_
41-6	6024-6027	and	_
41-7	6028-6038	anatomical	_
41-8	6039-6045	tissue	_
41-9	6046-6050	maps	_
41-10	6051-6055	were	_
41-11	6056-6066	determined	_
41-12	6067-6081	simultaneously	_
41-13	6082-6083	,	_
41-14	6084-6089	using	_
41-15	6090-6093	the	_
41-16	6094-6101	Segment	_
41-17	6102-6109	toolbox	_
41-18	6110-6111	.	_

42-1	6112-6122	Individual	_
42-2	6123-6133	anatomical	_
42-3	6134-6140	images	_
42-4	6141-6145	were	_
42-5	6146-6154	stripped	_
42-6	6155-6157	of	_
42-7	6158-6163	their	_
42-8	6164-6170	skulls	_
42-9	6171-6173	by	_
42-10	6174-6181	masking	_
42-11	6182-6185	the	_
42-12	6186-6200	bias-corrected	_
42-13	6201-6206	image	_
42-14	6207-6211	with	_
42-15	6212-6215	the	_
42-16	6216-6224	combined	_
42-17	6225-6231	tissue	_
42-18	6232-6237	masks	_
42-19	6238-6240	of	_
42-20	6241-6245	gray	_
42-21	6246-6252	matter	_
42-22	6253-6254	,	_
42-23	6255-6260	white	_
42-24	6261-6267	matter	_
42-25	6268-6269	,	_
42-26	6270-6273	and	_
42-27	6274-6277	CSF	_
42-28	6278-6279	.	_

43-1	6280-6283	The	_
43-2	6284-6294	functional	_
43-3	6295-6301	images	_
43-4	6302-6309	derived	_
43-5	6310-6314	from	_
43-6	6315-6326	realignment	_
43-7	6327-6331	were	_
43-8	6332-6344	coregistered	_
43-9	6345-6346	,	_
43-10	6347-6354	through	_
43-11	6355-6358	the	_
43-12	6359-6363	mean	_
43-13	6364-6369	image	_
43-14	6370-6371	,	_
43-15	6372-6374	to	_
43-16	6375-6378	the	_
43-17	6379-6393	skull-stripped	_
43-18	6394-6404	anatomical	_
43-19	6405-6410	image	_
43-20	6411-6412	(	_
43-21	6413-6423	Coregister	_
43-22	6424-6425	:	_
43-23	6426-6434	Estimate	_
43-24	6435-6436	,	_
43-25	6437-6442	using	_
43-26	6443-6453	normalized	_
43-27	6454-6460	mutual	_
43-28	6461-6472	information	_
43-29	6473-6474	)	_
43-30	6475-6476	.	_

44-1	6477-6489	Coregistered	_
44-2	6490-6496	images	_
44-3	6497-6501	were	_
44-4	6502-6506	then	_
44-5	6507-6517	normalized	_
44-6	6518-6519	(	_
44-7	6520-6529	Normalize	_
44-8	6530-6531	:	_
44-9	6532-6537	Write	_
44-10	6538-6539	)	_
44-11	6540-6542	to	_
44-12	6543-6546	MNI	_
44-13	6547-6555	template	_
44-14	6556-6561	space	_
44-15	6562-6566	with	_
44-16	6567-6570	the	_
44-17	6571-6580	nonlinear	_
44-18	6581-6586	warps	_
44-19	6587-6594	derived	_
44-20	6595-6599	from	_
44-21	6600-6603	the	_
44-22	6604-6611	Segment	_
44-23	6612-6616	tool	_
44-24	6617-6618	.	_

45-1	6619-6626	Finally	_
45-2	6627-6628	,	_
45-3	6629-6639	functional	_
45-4	6640-6646	images	_
45-5	6647-6651	were	_
45-6	6652-6658	masked	_
45-7	6659-6660	(	_
45-8	6661-6663	to	_
45-9	6664-6670	remove	_
45-10	6671-6674	the	_
45-11	6675-6680	skull	_
45-12	6681-6682	)	_
45-13	6683-6686	and	_
45-14	6687-6695	smoothed	_
45-15	6696-6697	(	_
45-16	6698-6699	8	_
45-17	6700-6702	mm	_
45-18	6703-6707	FWHM	_
45-19	6708-6716	Gaussian	_
45-20	6717-6723	kernel	_
45-21	6724-6725	)	_
45-22	6726-6728	to	_
45-23	6729-6739	facilitate	_
45-24	6740-6750	subsequent	_
45-25	6751-6759	analysis	_
45-26	6760-6761	.	_

46-1	6762-6772	Inspection	_
46-2	6773-6775	of	_
46-3	6776-6782	motion	_
46-4	6783-6793	correction	_
46-5	6794-6804	parameters	_
46-6	6805-6813	revealed	_
46-7	6814-6818	that	_
46-8	6819-6822	all	_
46-9	6823-6834	corrections	_
46-10	6835-6839	were	_
46-11	6840-6841	<	_
46-12	6842-6843	2	_
46-13	6844-6846	mm	_
46-14	6847-6848	.	_

47-1	6849-6857	Analyses	_
47-2	6858-6862	were	_
47-3	6863-6867	done	_
47-4	6868-6870	on	_
47-5	6871-6881	individual	_
47-6	6882-6887	level	_
47-7	6888-6891	and	_
47-8	6892-6893	a	_
47-9	6894-6899	group	_
47-10	6900-6905	level	_
47-11	6906-6907	.	_

48-1	6908-6915	Overall	_
48-2	6916-6923	effects	_
48-3	6924-6928	were	_
48-4	6929-6939	calculated	_
48-5	6940-6945	using	_
48-6	6946-6958	second-level	_
48-7	6959-6960	,	_
48-8	6961-6975	random-effects	_
48-9	6976-6984	analyses	_
48-10	6985-6987	of	_
48-11	6988-6992	this	_
48-12	6993-7001	contrast	_
48-13	7002-7005	for	_
48-14	7006-7009	all	_
48-15	7010-7021	individuals	_
48-16	7022-7023	,	_
48-17	7024-7028	with	_
48-18	7029-7036	cocaine	_
48-19	7037-7038	,	_
48-20	7039-7046	alcohol	_
48-21	7047-7048	,	_
48-22	7049-7052	and	_
48-23	7053-7061	nicotine	_
48-24	7062-7067	users	_
48-25	7068-7072	each	_
48-26	7073-7084	represented	_
48-27	7085-7087	as	_
48-28	7088-7089	a	_
48-29	7090-7096	unique	_
48-30	7097-7103	column	_
48-31	7104-7106	in	_
48-32	7107-7110	the	_
48-33	7111-7117	design	_
48-34	7118-7124	matrix	_
48-35	7125-7126	.	_

49-1	7127-7130	For	_
49-2	7131-7135	each	_
49-3	7136-7147	participant	_
49-4	7148-7149	,	_
49-5	7150-7161	first-level	_
49-6	7162-7163	,	_
49-7	7164-7177	fixed-effects	_
49-8	7178-7189	comparisons	_
49-9	7190-7194	were	_
49-10	7195-7199	made	_
49-11	7200-7202	to	_
49-12	7203-7212	determine	_
49-13	7213-7223	activation	_
49-14	7224-7230	during	_
49-15	7231-7243	drug/alcohol	_
49-16	7244-7247	cue	_
49-17	7248-7254	blocks	_
49-18	7255-7263	relative	_
49-19	7264-7266	to	_
49-20	7267-7274	neutral	_
49-21	7275-7281	blocks	_
49-22	7282-7287	using	_
49-23	7288-7291	the	_
49-24	7292-7299	general	_
49-25	7300-7306	linear	_
49-26	7307-7312	model	_
49-27	7313-7314	.	_

50-1	7315-7321	Motion	_
50-2	7322-7332	parameters	_
50-3	7333-7334	(	_
50-4	7335-7336	6	_
50-5	7337-7347	dimensions	_
50-6	7348-7349	:	_
50-7	7350-7351	x	_
50-8	7352-7353	,	_
50-9	7354-7355	y	_
50-10	7356-7357	,	_
50-11	7358-7359	z	_
50-12	7360-7361	,	_
50-13	7362-7365	yaw	_
50-14	7366-7367	,	_
50-15	7368-7373	pitch	_
50-16	7374-7375	,	_
50-17	7376-7380	roll	_
50-18	7381-7382	)	_
50-19	7383-7387	were	_
50-20	7388-7396	included	_
50-21	7397-7399	as	_
50-22	7400-7410	covariates	_
50-23	7411-7413	in	_
50-24	7414-7417	the	_
50-25	7418-7423	model	_
50-26	7424-7425	.	_

51-1	7426-7436	Voxel-wise	_
51-2	7437-7447	correction	_
51-3	7448-7451	for	_
51-4	7452-7460	multiple	_
51-5	7461-7472	comparisons	_
51-6	7473-7476	was	_
51-7	7477-7481	done	_
51-8	7482-7485	via	_
51-9	7486-7490	AFNI	_
51-10	7491-7492	’	_
51-11	7493-7494	s	_
51-12	7495-7505	3dClustSim	_
51-13	7506-7510	with	_
51-14	7511-7514	the	_
51-15	7515-7530	autocorrelation	_
51-16	7531-7537	module	_
51-17	7538-7545	enabled	_
51-18	7546-7547	(	_
51-19	7548-7552	2017	_
51-20	7553-7560	version	_
51-21	7561-7562	;	_
51-22	7563-7568	https	_
51-23	7569-7570	:	_
51-24	7571-7603	//afni.nimh.nih.gov/pub/dist/doc	_
51-25	7604-7605	)	_
51-26	7606-7607	.	_

52-1	7608-7616	Clusters	_
52-2	7617-7621	with	_
52-3	7622-7623	a	_
52-4	7624-7631	p-value	_
52-5	7632-7633	<	_
52-6	7634-7638	0.05	_
52-7	7639-7642	are	_
52-8	7643-7651	reported	_
52-9	7652-7653	(	_
52-10	7654-7664	determined	_
52-11	7665-7667	by	_
52-12	7668-7673	Monte	_
52-13	7674-7679	Carlo	_
52-14	7680-7690	simulation	_
52-15	7691-7692	;	_
52-16	7693-7704	voxel-level	_
52-17	7705-7714	threshold	_
52-18	7715-7717	of	_
52-19	7718-7719	p	_
52-20	7720-7721	<	_
52-21	7722-7727	0.005	_
52-22	7728-7731	for	_
52-23	7732-7734	at	_
52-24	7735-7740	least	_
52-25	7741-7743	48	_
52-26	7744-7754	contiguous	_
52-27	7755-7761	voxels	_
52-28	7762-7763	)	_
52-29	7764-7765	.	_

53-1	7766-7768	To	_
53-2	7769-7780	investigate	_
53-3	7781-7791	individual	_
53-4	7792-7803	variability	_
53-5	7804-7805	,	_
53-6	7806-7809	the	_
53-7	7810-7817	primary	_
53-8	7818-7823	locus	_
53-9	7824-7826	of	_
53-10	7827-7835	activity	_
53-11	7836-7838	in	_
53-12	7839-7842	the	_
53-13	7843-7849	during	_
53-14	7850-7862	drug-related	_
53-15	7863-7867	cues	_
53-16	7868-7876	relative	_
53-17	7877-7879	to	_
53-18	7880-7887	neutral	_
53-19	7888-7892	cues	_
53-20	7893-7894	(	_
53-21	7895-7896	“	_
53-22	7897-7900	hot	_
53-23	7901-7905	spot	_
53-24	7906-7907	”	_
53-25	7908-7909	)	_
53-26	7910-7913	was	_
53-27	7914-7922	isolated	_
53-28	7923-7926	for	_
53-29	7927-7931	each	_
53-30	7932-7942	individual	_
53-31	7943-7945	by	_
53-32	7946-7954	locating	_
53-33	7955-7958	the	_
53-34	7959-7964	local	_
53-35	7965-7972	maximum	_
53-36	7973-7978	voxel	_
53-37	7979-7980	(	_
53-38	7981-7982	x	_
53-39	7983-7984	,	_
53-40	7985-7986	y	_
53-41	7987-7988	,	_
53-42	7989-7990	z	_
53-43	7991-7992	,	_
53-44	7993-7996	MNI	_
53-45	7997-8008	coordinates	_
53-46	8009-8010	)	_
53-47	8011-8017	within	_
53-48	8018-8021	the	_
53-49	8022-8026	most	_
53-50	8027-8038	significant	_
53-51	8039-8046	cluster	_
53-52	8047-8049	of	_
53-53	8050-8058	activity	_
53-54	8059-8060	(	_
53-55	8061-8062	p	_
53-56	8063-8064	<	_
53-57	8065-8069	0.05	_
53-58	8070-8071	,	_
53-59	8072-8081	corrected	_
53-60	8082-8084	at	_
53-61	8085-8088	the	_
53-62	8089-8096	cluster	_
53-63	8097-8102	level	_
53-64	8103-8104	)	_
53-65	8105-8106	.	_

54-1	8107-8110	The	_
54-2	8111-8119	analysis	_
54-3	8120-8123	was	_
54-4	8124-8131	limited	_
54-5	8132-8134	to	_
54-6	8135-8143	cortical	_
54-7	8144-8149	areas	_
54-8	8150-8152	as	_
54-9	8153-8156	one	_
54-10	8157-8159	of	_
54-11	8160-8163	the	_
54-12	8164-8168	aims	_
54-13	8169-8171	of	_
54-14	8172-8176	this	_
54-15	8177-8182	study	_
54-16	8183-8186	was	_
54-17	8187-8189	to	_
54-18	8190-8198	identify	_
54-19	8199-8208	potential	_
54-20	8209-8216	frontal	_
54-21	8217-8224	targets	_
54-22	8225-8228	for	_
54-23	8229-8236	current	_
54-24	8237-8248	noninvasive	_
54-25	8249-8254	brain	_
54-26	8255-8266	stimulation	_
54-27	8267-8274	methods	_
54-28	8275-8279	such	_
54-29	8280-8282	as	_
54-30	8283-8286	TMS	_
54-31	8287-8288	.	_

55-1	8289-8292	The	_
55-2	8293-8297	mask	_
55-3	8298-8306	included	_
55-4	8307-8310	the	_
55-5	8311-8320	following	_
55-6	8321-8330	bilateral	_
55-7	8331-8338	regions	_
55-8	8339-8341	of	_
55-9	8342-8350	interest	_
55-10	8351-8360	extracted	_
55-11	8361-8365	from	_
55-12	8366-8369	the	_
55-13	8370-8382	standardized	_
55-14	8383-8391	WFU_Pick	_
55-15	8392-8397	atlas	_
55-16	8398-8409	implemented	_
55-17	8410-8412	in	_
55-18	8413-8419	MATLAB	_
55-19	8420-8421	(	_
55-20	8422-8427	https	_
55-21	8428-8429	:	_
55-22	8430-8468	//www.nitrc.org/projects/wfu_pickatlas	_
55-23	8469-8470	)	_
55-24	8471-8472	:	_
55-25	8473-8481	anterior	_
55-26	8482-8491	cingulate	_
55-27	8492-8498	cortex	_
55-28	8499-8500	,	_
55-29	8501-8507	middle	_
55-30	8508-8515	frontal	_
55-31	8516-8521	gyrus	_
55-32	8522-8523	,	_
55-33	8524-8530	medial	_
55-34	8531-8538	frontal	_
55-35	8539-8544	gyrus	_
55-36	8545-8546	,	_
55-37	8547-8555	inferior	_
55-38	8556-8563	frontal	_
55-39	8564-8569	gyrus	_
55-40	8570-8571	,	_
55-41	8572-8575	and	_
55-42	8576-8584	superior	_
55-43	8585-8592	frontal	_
55-44	8593-8598	gyrus	_
55-45	8599-8600	(	_
55-46	8601-8603	2D	_
55-47	8604-8612	dilation	_
55-48	8613-8618	value	_
55-49	8619-8620	:	_
55-50	8621-8622	3	_
55-51	8623-8624	)	_
55-52	8625-8626	.	_

56-1	8627-8634	Spatial	_
56-2	8635-8645	dispersion	_
56-3	8646-8648	of	_
56-4	8649-8652	the	_
56-5	8653-8654	“	_
56-6	8655-8658	hot	_
56-7	8659-8664	spots	_
56-8	8665-8666	”	_
56-9	8667-8668	,	_
56-10	8669-8673	were	_
56-11	8674-8687	characterized	_
56-12	8688-8691	via	_
56-13	8692-8699	k-means	_
56-14	8700-8710	clustering	_
56-15	8711-8712	(	_
56-16	8713-8715	as	_
56-17	8716-8727	implemented	_
56-18	8728-8730	in	_
56-19	8731-8737	MATLAB	_
56-20	8738-8741	and	_
56-21	8742-8755	cross-checked	_
56-22	8756-8760	with	_
56-23	8761-8762	R	_
56-24	8763-8764	)	_
56-25	8765-8766	.	_

57-1	8767-8774	K-means	_
57-2	8775-8785	clustering	_
57-3	8786-8788	as	_
57-4	8789-8800	implemented	_
57-5	8801-8803	in	_
57-6	8804-8810	Matlab	_
57-7	8811-8815	used	_
57-8	8816-8819	the	_
57-9	8820-8821	K	_
57-10	8822-8823	+	_
57-11	8824-8825	+	_
57-12	8826-8835	algorithm	_
57-13	8836-8837	,	_
57-14	8838-8840	an	_
57-15	8841-8850	iterative	_
57-16	8851-8852	,	_
57-17	8853-8870	data-partitioning	_
57-18	8871-8880	algorithm	_
57-19	8881-8885	that	_
57-20	8886-8893	assigns	_
57-21	8894-8897	the	_
57-22	8898-8903	total	_
57-23	8904-8910	number	_
57-24	8911-8913	of	_
57-25	8914-8926	observations	_
57-26	8927-8928	(	_
57-27	8929-8932	e.g	_
57-28	8933-8934	.	_

58-1	8935-8938	MNI	_
58-2	8939-8950	coordinates	_
58-3	8951-8954	for	_
58-4	8955-8963	clusters	_
58-5	8964-8977	significantly	_
58-6	8978-8987	activated	_
58-7	8988-8990	by	_
58-8	8991-9000	drug-cues	_
58-9	9001-9002	)	_
58-10	9003-9005	to	_
58-11	9006-9013	exactly	_
58-12	9014-9017	one	_
58-13	9018-9020	of	_
58-14	9021-9022	‘	_
58-15	9023-9024	k	_
58-16	9025-9026	’	_
58-17	9027-9035	clusters	_
58-18	9036-9043	defined	_
58-19	9044-9046	by	_
58-20	9047-9056	centroids	_
58-21	9057-9058	,	_
58-22	9059-9064	where	_
58-23	9065-9066	‘	_
58-24	9067-9068	k	_
58-25	9069-9070	‘	_
58-26	9071-9073	is	_
58-27	9074-9080	chosen	_
58-28	9081-9087	before	_
58-29	9088-9091	the	_
58-30	9092-9101	algorithm	_
58-31	9102-9108	starts	_
58-32	9109-9110	.	_

59-1	9111-9114	The	_
59-2	9115-9116	K	_
59-3	9117-9118	+	_
59-4	9119-9120	+	_
59-5	9121-9130	algorithm	_
59-6	9131-9133	is	_
59-7	9134-9135	a	_
59-8	9136-9145	two-phase	_
59-9	9146-9153	process	_
59-10	9154-9159	which	_
59-11	9160-9164	uses	_
59-12	9165-9170	batch	_
59-13	9171-9174	and	_
59-14	9175-9181	online	_
59-15	9182-9189	updates	_
59-16	9190-9192	to	_
59-17	9193-9201	minimize	_
59-18	9202-9205	the	_
59-19	9206-9209	sum	_
59-20	9210-9212	of	_
59-21	9213-9230	point-to-centroid	_
59-22	9231-9240	distances	_
59-23	9241-9243	in	_
59-24	9244-9245	k	_
59-25	9246-9254	clusters	_
59-26	9255-9256	.	_

60-1	9257-9269	Specifically	_
60-2	9270-9271	,	_
60-3	9272-9281	following	_
60-4	9282-9285	the	_
60-5	9286-9293	initial	_
60-6	9294-9300	random	_
60-7	9301-9308	seeding	_
60-8	9309-9311	of	_
60-9	9312-9323	k-centroids	_
60-10	9324-9325	,	_
60-11	9326-9327	a	_
60-12	9328-9336	distance	_
60-13	9337-9339	is	_
60-14	9340-9350	calculated	_
60-15	9351-9355	from	_
60-16	9356-9360	each	_
60-17	9361-9366	point	_
60-18	9367-9369	to	_
60-19	9370-9374	each	_
60-20	9375-9383	centroid	_
60-21	9384-9387	and	_
60-22	9388-9392	that	_
60-23	9393-9398	point	_
60-24	9399-9401	is	_
60-25	9402-9412	classified	_
60-26	9413-9415	as	_
60-27	9416-9417	a	_
60-28	9418-9424	member	_
60-29	9425-9427	of	_
60-30	9428-9429	a	_
60-31	9430-9435	given	_
60-32	9436-9444	centroid	_
60-33	9445-9446	.	_

61-1	9447-9451	This	_
61-2	9452-9454	is	_
61-3	9455-9463	reseated	_
61-4	9464-9465	,	_
61-5	9466-9469	and	_
61-6	9470-9478	centroid	_
61-7	9479-9488	locations	_
61-8	9489-9492	are	_
61-9	9493-9503	reassigned	_
61-10	9504-9506	if	_
61-11	9507-9508	a	_
61-12	9509-9521	reassignment	_
61-13	9522-9531	decreases	_
61-14	9532-9535	the	_
61-15	9536-9539	sum	_
61-16	9540-9542	of	_
61-17	9543-9546	the	_
61-18	9547-9561	within-cluster	_
61-19	9562-9565	sum	_
61-20	9566-9568	of	_
61-21	9569-9576	squared	_
61-22	9577-9594	point-to-centroid	_
61-23	9595-9603	distance	_
61-24	9604-9605	.	_

62-1	9606-9609	For	_
62-2	9610-9613	the	_
62-3	9614-9621	present	_
62-4	9622-9627	study	_
62-5	9628-9632	this	_
62-6	9633-9642	procedure	_
62-7	9643-9646	was	_
62-8	9647-9655	repeated	_
62-9	9656-9660	1000	_
62-10	9661-9666	times	_
62-11	9667-9671	with	_
62-12	9672-9678	random	_
62-13	9679-9686	seeding	_
62-14	9687-9688	.	_

63-1	9689-9693	This	_
63-2	9694-9697	was	_
63-3	9698-9702	done	_
63-4	9703-9706	for	_
63-5	9707-9710	the	_
63-6	9711-9715	full	_
63-7	9716-9726	complement	_
63-8	9727-9729	of	_
63-9	9730-9736	points	_
63-10	9737-9738	(	_
63-11	9739-9740	n	_
63-12	9741-9742	=	_
63-13	9743-9746	261	_
63-14	9747-9748	)	_
63-15	9749-9751	as	_
63-16	9752-9756	well	_
63-17	9757-9759	as	_
63-18	9760-9763	for	_
63-19	9764-9765	a	_
63-20	9766-9776	restricted	_
63-21	9777-9781	data	_
63-22	9782-9785	set	_
63-23	9786-9793	limited	_
63-24	9794-9796	to	_
63-25	9797-9800	one	_
63-26	9801-9808	cluster	_
63-27	9809-9812	per	_
63-28	9813-9823	individual	_
63-29	9824-9825	(	_
63-30	9826-9827	n	_
63-31	9828-9829	=	_
63-32	9830-9833	103	_
63-33	9834-9835	)	_
63-34	9836-9837	.	_

64-1	9838-9840	In	_
64-2	9841-9845	this	_
64-3	9846-9856	experiment	_
64-4	9857-9859	we	_
64-5	9860-9868	utilized	_
64-6	9869-9870	k	_
64-7	9871-9877	values	_
64-8	9878-9880	of	_
64-9	9881-9885	2–10	_
64-10	9886-9888	to	_
64-11	9889-9897	evaluate	_
64-12	9898-9901	the	_
64-13	9902-9913	possibility	_
64-14	9914-9918	that	_
64-15	9919-9924	there	_
64-16	9925-9930	could	_
64-17	9931-9933	be	_
64-18	9934-9936	up	_
64-19	9937-9939	to	_
64-20	9940-9942	10	_
64-21	9943-9949	unique	_
64-22	9950-9958	clusters	_
64-23	9959-9960	.	_

65-1	9961-9964	The	_
65-2	9965-9972	optimal	_
65-3	9973-9981	solution	_
65-4	9982-9985	was	_
65-5	9986-9993	derived	_
65-6	9994-9997	via	_
65-7	9998-10001	the	_
65-8	10002-10005	use	_
65-9	10006-10008	of	_
65-10	10009-10019	silhouette	_
65-11	10020-10025	plots	_
65-12	10026-10027	.	_

66-1	10028-10031	For	_
66-2	10032-10036	each	_
66-3	10037-10044	cluster	_
66-4	10045-10048	the	_
66-5	10049-10057	centroid	_
66-6	10058-10063	vales	_
66-7	10064-10067	was	_
66-8	10068-10076	recorded	_
66-9	10077-10079	as	_
66-10	10080-10084	well	_
66-11	10085-10087	as	_
66-12	10088-10091	the	_
66-13	10092-10099	average	_
66-14	10100-10103	and	_
66-15	10104-10111	maximum	_
66-16	10112-10120	distance	_
66-17	10121-10123	of	_
66-18	10124-10127	any	_
66-19	10128-10133	given	_
66-20	10134-10139	point	_
66-21	10140-10142	to	_
66-22	10143-10146	the	_
66-23	10147-10153	center	_
66-24	10154-10156	of	_
66-25	10157-10160	the	_
66-26	10161-10169	centroid	_
66-27	10170-10171	.	_

67-1	10172-10179	Posthoc	_
67-2	10180-10185	tests	_
67-3	10186-10190	were	_
67-4	10191-10200	performed	_
67-5	10201-10203	to	_
67-6	10204-10213	determine	_
67-7	10214-10221	whether	_
67-8	10222-10225	the	_
67-9	10226-10231	areas	_
67-10	10232-10234	of	_
67-11	10235-10239	peak	_
67-12	10240-10248	activity	_
67-13	10249-10252	for	_
67-14	10253-10260	cocaine	_
67-15	10261-10275	cue-reactivity	_
67-16	10276-10277	,	_
67-17	10278-10285	alcohol	_
67-18	10286-10300	cue-reactivity	_
67-19	10301-10302	,	_
67-20	10303-10306	and	_
67-21	10307-10314	smoking	_
67-22	10315-10329	cue-reactivity	_
67-23	10330-10334	were	_
67-24	10335-10342	equally	_
67-25	10343-10354	distributed	_
67-26	10355-10360	among	_
67-27	10361-10364	the	_
67-28	10365-10374	centroids	_
67-29	10375-10376	(	_
67-30	10377-10387	Chi-square	_
67-31	10388-10389	,	_
67-32	10390-10393	IBM	_
67-33	10394-10398	SPSS	_
67-34	10399-10409	Statistics	_
67-35	10410-10416	ver.19	_
67-36	10417-10418	,	_
67-37	10419-10420	p	_
67-38	10421-10422	<	_
67-39	10423-10427	0.05	_
67-40	10428-10429	)	_
67-41	10430-10431	.	_

68-1	10432-10435	The	_
68-2	10436-10448	distribution	_
68-3	10449-10451	of	_
68-4	10452-10458	gender	_
68-5	10459-10462	was	_
68-6	10463-10467	also	_
68-7	10468-10480	investigated	_
68-8	10481-10486	given	_
68-9	10487-10492	prior	_
68-10	10493-10498	study	_
68-11	10499-10503	from	_
68-12	10504-10507	our	_
68-13	10508-10513	group	_
68-14	10514-10519	which	_
68-15	10520-10528	suggests	_
68-16	10529-10534	males	_
68-17	10535-10538	may	_
68-18	10539-10543	have	_
68-19	10544-10545	a	_
68-20	10546-10550	more	_
68-21	10551-10558	uniform	_
68-22	10559-10571	distribution	_
68-23	10572-10576	than	_
68-24	10577-10584	females	_
68-25	10585-10586	.	_

69-1	10587-10590	TMS	_
69-2	10591-10599	distance	_
69-3	10600-10607	methods	_
69-4	10608-10611	The	_
69-5	10612-10616	data	_
69-6	10617-10621	from	_
69-7	10622-10625	the	_
69-8	10626-10636	individual	_
69-9	10637-10642	level	_
69-10	10643-10651	analysis	_
69-11	10652-10653	(	_
69-12	10654-10655	‘	_
69-13	10656-10664	hotspots	_
69-14	10665-10666	’	_
69-15	10667-10668	)	_
69-16	10669-10673	were	_
69-17	10674-10678	used	_
69-18	10679-10681	to	_
69-19	10682-10691	determine	_
69-20	10692-10695	the	_
69-21	10696-10701	scalp	_
69-22	10702-10711	locations	_
69-23	10712-10713	(	_
69-24	10714-10717	EEG	_
69-25	10718-10723	10-10	_
69-26	10724-10735	coordinates	_
69-27	10736-10737	)	_
69-28	10738-10742	that	_
69-29	10743-10747	were	_
69-30	10748-10755	closest	_
69-31	10756-10758	to	_
69-32	10759-10762	the	_
69-33	10763-10771	greatest	_
69-34	10772-10778	number	_
69-35	10779-10781	of	_
69-36	10782-10788	points	_
69-37	10789-10802	significantly	_
69-38	10803-10812	activated	_
69-39	10813-10815	by	_
69-40	10816-10820	drug	_
69-41	10821-10825	cues	_
69-42	10826-10827	.	_

70-1	10828-10831	The	_
70-2	10832-10841	Euclidean	_
70-3	10842-10851	distances	_
70-4	10852-10856	from	_
70-5	10857-10861	each	_
70-6	10862-10869	hotspot	_
70-7	10870-10872	to	_
70-8	10873-10876	EEG	_
70-9	10877-10882	10-10	_
70-10	10883-10889	system	_
70-11	10890-10901	coordinates	_
70-12	10902-10906	were	_
70-13	10907-10917	calculated	_
70-14	10918-10919	.	_

71-1	10920-10922	We	_
71-2	10923-10932	evaluated	_
71-3	10933-10936	the	_
71-4	10937-10947	percentage	_
71-5	10948-10950	of	_
71-6	10951-10959	hotspots	_
71-7	10960-10964	that	_
71-8	10965-10970	would	_
71-9	10971-10973	be	_
71-10	10974-10981	reached	_
71-11	10982-10984	at	_
71-12	10985-10992	several	_
71-13	10993-11002	distances	_
71-14	11003-11004	(	_
71-15	11005-11008	2–5	_
71-16	11009-11011	cm	_
71-17	11012-11013	)	_
71-18	11014-11019	given	_
71-19	11020-11024	that	_
71-20	11025-11028	the	_
71-21	11029-11040	penetration	_
71-22	11041-11056	characteristics	_
71-23	11057-11059	of	_
71-24	11060-11064	rTMS	_
71-25	11065-11068	are	_
71-26	11069-11078	dependent	_
71-27	11079-11081	on	_
71-28	11082-11086	coil	_
71-29	11087-11091	size	_
71-30	11092-11093	.	_

72-1	11094-11102	Analyses	_
72-2	11103-11107	were	_
72-3	11108-11112	done	_
72-4	11113-11116	for	_
72-5	11117-11120	the	_
72-6	11121-11125	full	_
72-7	11126-11136	complement	_
72-8	11137-11139	of	_
72-9	11140-11152	participants	_
72-10	11153-11155	as	_
72-11	11156-11160	well	_
72-12	11161-11163	as	_
72-13	11164-11173	subgroups	_
72-14	11174-11181	defined	_
72-15	11182-11184	by	_
72-16	11185-11188	the	_
72-17	11189-11199	individual	_
72-18	11200-11201	’	_
72-19	11202-11203	s	_
72-20	11204-11208	drug	_
72-21	11209-11211	of	_
72-22	11212-11218	choice	_
72-23	11219-11220	.	_

73-1	11221-11225	Code	_
73-2	11226-11238	availability	_
73-3	11239-11248	Computing	_
73-4	11249-11257	programs	_
73-5	11258-11261	and	_
73-6	11262-11272	customized	_
73-7	11273-11280	scripts	_
73-8	11281-11285	used	_
73-9	11286-11288	in	_
73-10	11289-11293	this	_
73-11	11294-11304	experiment	_
73-12	11305-11308	are	_
73-13	11309-11312	all	_
73-14	11313-11322	available	_
73-15	11323-11326	for	_
73-16	11327-11331	free	_
73-17	11332-11334	to	_
73-18	11335-11338	the	_
73-19	11339-11348	community	_
73-20	11349-11351	by	_
73-21	11352-11362	contacting	_
73-22	11363-11366	the	_
73-23	11367-11380	corresponding	_
73-24	11381-11387	author	_
73-25	11388-11389	.	_

